Evidence map›Paper›PMID 39418288›Full record

ArticlePloS one2024

SARS-CoV-2 variant survey: Comparison of RT-PCR screening with TGS and variant distribution across two divisions of Bangladesh.

Zannat Kawser, Saikt Rahman, Emilie Westeel, Mohammad Tanbir Habib, Mohabbat Hossain, Md Rakibul Hassan Bulbul, Sharmin Aktar Mukta, Md Zahirul Islam, Md Zakir Hossain, Mokibul Hassan Afrad and 6 more

Abstract readComparative Study
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zannat KawserInstitute for Developing Science and Health Initiatives, Dhaka, Bangladesh.ORCID 0000-0001-7628-137X
Saikt RahmanInstitute for Developing Science and Health Initiatives, Dhaka, Bangladesh.ORCID 0009-0000-2432-5588
Emilie WesteelFondation Mérieux, Direction Médicale et Scientifique, Lyon, France.
Mohammad Tanbir HabibInstitute for Developing Science and Health Initiatives, Dhaka, Bangladesh.
Mohabbat HossainInstitute for Developing Science and Health Initiatives, Dhaka, Bangladesh.
Md Rakibul Hassan BulbulInstitute for Developing Science and Health Initiatives, Dhaka, Bangladesh.
Sharmin Aktar MuktaInstitute for Developing Science and Health Initiatives, Dhaka, Bangladesh.ORCID 0009-0006-8608-8753
Md Zahirul IslamInstitute for Developing Science and Health Initiatives, Dhaka, Bangladesh.
Md Zakir HossainBangladesh Institute of Tropical and Infectious Disease (BITID), Fouzderhat, Chittagong, Bangladesh.
Mokibul Hassan AfradInternational Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh.
Manjur Hossain KhanInstitute of Epidemiology, Disease Control, and Research, Dhaka, Bangladesh.
Tahmina ShirinInstitute of Epidemiology, Disease Control, and Research, Dhaka, Bangladesh.
Md Shakeel AhmedBangladesh Institute of Tropical and Infectious Disease (BITID), Fouzderhat, Chittagong, Bangladesh.ORCID 0000-0002-3405-2146
Jean-Luc BerlandFondation Mérieux, Direction Médicale et Scientifique, Lyon, France.ORCID 0000-0002-6337-3715
Florence Komurian-PradelFondation Mérieux, Direction Médicale et Scientifique, Lyon, France.ORCID 0000-0002-1023-0796
Firdausi QadriInstitute for Developing Science and Health Initiatives, Dhaka, Bangladesh.

Funding

Training program in vaccine development and public healthD43TW005572 · FIC · MASSACHUSETTS GENERAL HOSPITAL · PI QADRI, FIRDAUSI, RYAN, EDWARD T. · 2000 to 2025
$5.4M
FIC NIH HHS D43 TW005572
6 · The paper itself

Abstract

backgroundThe widespread increase in multiple variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) since 2020 is causing significant health concerns worldwide. While whole-genome sequencing (WGS) has played a leading role in surveillance programs, many local laboratories lack the expertise and resources. Thus, we aimed to investigate the circulating SARS-CoV-2 variants and evaluate the performance of multiplexed real-time reverse transcription-PCR (RT-PCR) for screening and monitoring the emergence of new SARS-CoV-2 variants in Bangladesh.

methodsA total of 600 confirmed SARS-CoV-2-positive cases were enrolled either prospectively or retrospectively from two divisions of Bangladesh. The samples were screened by variant RT-PCR targeting five mutations of the spike gene (N501Y, P681R, L452R, E484K, E484Q). A subsample of the study population was also selected for third-generation sequencing (TGS) and the results were compared to the variant RT-PCR screening. An in-depth comparison was made between the two methods in terms of congruence and cost-benefit.

resultSeven variants were detected among samples, with similar distributions of the variants across both divisions. Variant RT-PCR for the targeted mutations lead to a 98.5% call rate; only nine samples failed to be determined. No association was found regarding the demographic features, clinical criteria, or routine RT-PCR Ct values across the variants. The clade diversity of the sequenced subpopulation (n = 99) exhibited similar distributions across the two study sites and other epidemiologic variables. Variant RT-PCR successfully distinguished variants of concern (VOCs) and variants of interest (VOIs); however, 8% discrepancy was observed for the closest lineages. Moreover, the variant RT-PCR represented an ideal balance of cost, time, and accuracy that outweigh their limitations.

conclusionBased on the strong agreement of variant RT-PCR with TGS, such rapid, easily accessible approaches of rapid strain typing are essential in the context of pandemic responses to guide both treatment decisions and public health measures.

Indexed as

COVID-19SARS-CoV-2AdultBangladeshCOVID-19 Nucleic Acid TestingFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationProspective StudiesReal-Time Polymerase Chain ReactionRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionSpike Glycoprotein, CoronavirusSpike Glycoprotein, Coronavirus

Identifiers

PMID39418288
PMCPMC11486398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.